FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2891443166> ?p ?o ?g. }

• W2891443166 endingPage "838" @default.
• W2891443166 startingPage "829" @default.
• W2891443166 abstract "PurposeThere is an urgent need for a more effective intervention to slow or prevent progression of age-related macular degeneration (AMD) from its early stages to vision-threatening late complications. Subthreshold nanosecond laser (SNL) treatment has shown promise in preclinical studies and a pilot study in intermediate AMD (iAMD) as a potential treatment. We aimed to evaluate the safety of SNL treatment in iAMD and its efficacy for slowing progression to late AMD.DesignThe Laser Intervention in Early Stages of Age-Related Macular Degeneration (LEAD) study is a 36-month, multicenter, randomized, sham-controlled trial.ParticipantsTwo hundred ninety-two participants with bilateral large drusen and without OCT signs of atrophy.MethodsParticipants were assigned randomly to receive Retinal Rejuvenation Therapy (2RT®; Ellex Pty Ltd, Adelaide, Australia) SNL or sham treatment to the study eye at 6-monthly intervals.Main Outcome MeasuresThe primary efficacy outcome was the time to development of late AMD defined by multimodal imaging (MMI). Safety was assessed by adverse events.ResultsOverall, progression to late AMD was not slowed significantly with SNL treatment compared with sham treatment (adjusted hazard ratio [HR], 0.61; 95% confidence interval [CI], 0.33–1.14; P = 0.122). However, a post hoc analysis showed evidence of effect modification based on the coexistence of reticular pseudodrusen (RPD; adjusted interaction P = 0.002), where progression was slowed for the 222 participants (76.0%) without coexistent RPD at baseline (adjusted HR, 0.23; 95% CI, 0.09–0.59; P = 0.002), whereas an increased progression rate (adjusted HR, 2.56; 95% CI, 0.80–8.18; P = 0.112) was observed for the 70 participants (24.0%) with RPD with SNL treatment. Differences between the groups in serious adverse events were not significant.ConclusionsIn participants with iAMD without MMI-detected signs of late AMD, no significant difference in the overall progression rate to late AMD between those receiving SNL and sham treatment were observed. However, SNL treatment may have a role in slowing progression for those without coexistent RPD and may be inappropriate in those with RPD, warranting caution when considering treatment in clinical phenotypes with RPD. Our findings provide compelling evidence for further trials of the 2RT® laser, but they should not be extrapolated to other short-pulse lasers. There is an urgent need for a more effective intervention to slow or prevent progression of age-related macular degeneration (AMD) from its early stages to vision-threatening late complications. Subthreshold nanosecond laser (SNL) treatment has shown promise in preclinical studies and a pilot study in intermediate AMD (iAMD) as a potential treatment. We aimed to evaluate the safety of SNL treatment in iAMD and its efficacy for slowing progression to late AMD. The Laser Intervention in Early Stages of Age-Related Macular Degeneration (LEAD) study is a 36-month, multicenter, randomized, sham-controlled trial. Two hundred ninety-two participants with bilateral large drusen and without OCT signs of atrophy. Participants were assigned randomly to receive Retinal Rejuvenation Therapy (2RT®; Ellex Pty Ltd, Adelaide, Australia) SNL or sham treatment to the study eye at 6-monthly intervals. The primary efficacy outcome was the time to development of late AMD defined by multimodal imaging (MMI). Safety was assessed by adverse events. Overall, progression to late AMD was not slowed significantly with SNL treatment compared with sham treatment (adjusted hazard ratio [HR], 0.61; 95% confidence interval [CI], 0.33–1.14; P = 0.122). However, a post hoc analysis showed evidence of effect modification based on the coexistence of reticular pseudodrusen (RPD; adjusted interaction P = 0.002), where progression was slowed for the 222 participants (76.0%) without coexistent RPD at baseline (adjusted HR, 0.23; 95% CI, 0.09–0.59; P = 0.002), whereas an increased progression rate (adjusted HR, 2.56; 95% CI, 0.80–8.18; P = 0.112) was observed for the 70 participants (24.0%) with RPD with SNL treatment. Differences between the groups in serious adverse events were not significant. In participants with iAMD without MMI-detected signs of late AMD, no significant difference in the overall progression rate to late AMD between those receiving SNL and sham treatment were observed. However, SNL treatment may have a role in slowing progression for those without coexistent RPD and may be inappropriate in those with RPD, warranting caution when considering treatment in clinical phenotypes with RPD. Our findings provide compelling evidence for further trials of the 2RT® laser, but they should not be extrapolated to other short-pulse lasers." @default.
• W2891443166 created "2018-09-27" @default.
• W2891443166 creator A5006359631 @default.
• W2891443166 creator A5019510374 @default.
• W2891443166 creator A5019521414 @default.
• W2891443166 creator A5021125993 @default.
• W2891443166 creator A5035344930 @default.
• W2891443166 creator A5035472393 @default.
• W2891443166 creator A5045316705 @default.
• W2891443166 creator A5048943367 @default.
• W2891443166 creator A5049667120 @default.
• W2891443166 creator A5049716460 @default.
• W2891443166 creator A5050220299 @default.
• W2891443166 creator A5050750002 @default.
• W2891443166 creator A5051997081 @default.
• W2891443166 creator A5061915670 @default.
• W2891443166 creator A5063669925 @default.
• W2891443166 creator A5066629372 @default.
• W2891443166 creator A5070822586 @default.
• W2891443166 creator A5071862143 @default.
• W2891443166 creator A5080650805 @default.
• W2891443166 creator A5086141217 @default.
• W2891443166 creator A5089656020 @default.
• W2891443166 creator A5090911149 @default.
• W2891443166 date "2019-06-01" @default.
• W2891443166 modified "2023-10-15" @default.
• W2891443166 title "Subthreshold Nanosecond Laser Intervention in Age-Related Macular Degeneration" @default.
• W2891443166 cites W1507327514 @default.
• W2891443166 cites W1586789952 @default.
• W2891443166 cites W1965478508 @default.
• W2891443166 cites W1972642682 @default.
• W2891443166 cites W1973167901 @default.
• W2891443166 cites W1982723437 @default.
• W2891443166 cites W1983972989 @default.
• W2891443166 cites W1993825155 @default.
• W2891443166 cites W1997766361 @default.
• W2891443166 cites W2018824760 @default.
• W2891443166 cites W2019947342 @default.
• W2891443166 cites W2033376221 @default.
• W2891443166 cites W2045011938 @default.
• W2891443166 cites W2112641578 @default.
• W2891443166 cites W2124415048 @default.
• W2891443166 cites W2128575831 @default.
• W2891443166 cites W2150098643 @default.
• W2891443166 cites W2168558228 @default.
• W2891443166 cites W2314510813 @default.
• W2891443166 cites W2320696053 @default.
• W2891443166 cites W2323021211 @default.
• W2891443166 cites W2419255724 @default.
• W2891443166 cites W2554478857 @default.
• W2891443166 cites W2583781348 @default.
• W2891443166 cites W2598520882 @default.
• W2891443166 cites W2604036950 @default.
• W2891443166 cites W2736649496 @default.
• W2891443166 cites W2766820003 @default.
• W2891443166 cites W2768917396 @default.
• W2891443166 cites W2785954970 @default.
• W2891443166 cites W2807327270 @default.
• W2891443166 doi "https://doi.org/10.1016/j.ophtha.2018.09.015" @default.
• W2891443166 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30244144" @default.
• W2891443166 hasPublicationYear "2019" @default.
• W2891443166 type Work @default.
• W2891443166 sameAs 2891443166 @default.
• W2891443166 citedByCount "130" @default.
• W2891443166 countsByYear W28914431662018 @default.
• W2891443166 countsByYear W28914431662019 @default.
• W2891443166 countsByYear W28914431662020 @default.
• W2891443166 countsByYear W28914431662021 @default.
• W2891443166 countsByYear W28914431662022 @default.
• W2891443166 countsByYear W28914431662023 @default.
• W2891443166 crossrefType "journal-article" @default.
• W2891443166 hasAuthorship W2891443166A5006359631 @default.
• W2891443166 hasAuthorship W2891443166A5019510374 @default.
• W2891443166 hasAuthorship W2891443166A5019521414 @default.
• W2891443166 hasAuthorship W2891443166A5021125993 @default.
• W2891443166 hasAuthorship W2891443166A5035344930 @default.
• W2891443166 hasAuthorship W2891443166A5035472393 @default.
• W2891443166 hasAuthorship W2891443166A5045316705 @default.
• W2891443166 hasAuthorship W2891443166A5048943367 @default.
• W2891443166 hasAuthorship W2891443166A5049667120 @default.
• W2891443166 hasAuthorship W2891443166A5049716460 @default.
• W2891443166 hasAuthorship W2891443166A5050220299 @default.
• W2891443166 hasAuthorship W2891443166A5050750002 @default.
• W2891443166 hasAuthorship W2891443166A5051997081 @default.
• W2891443166 hasAuthorship W2891443166A5061915670 @default.
• W2891443166 hasAuthorship W2891443166A5063669925 @default.
• W2891443166 hasAuthorship W2891443166A5066629372 @default.
• W2891443166 hasAuthorship W2891443166A5070822586 @default.
• W2891443166 hasAuthorship W2891443166A5071862143 @default.
• W2891443166 hasAuthorship W2891443166A5080650805 @default.
• W2891443166 hasAuthorship W2891443166A5086141217 @default.
• W2891443166 hasAuthorship W2891443166A5089656020 @default.
• W2891443166 hasAuthorship W2891443166A5090911149 @default.
• W2891443166 hasBestOaLocation W28914431661 @default.
• W2891443166 hasConcept C118487528 @default.
• W2891443166 hasConcept C126322002 @default.
• W2891443166 hasConcept C141071460 @default.
• W2891443166 hasConcept C168563851 @default.

• next